• Natera entered a strategic collaboration with CytoDyn to support CytoDyn’s metastatic colorectal cancer program for leronlimab using ctDNA analysis.
• Signatera will test samples from CytoDyn’s CLOVER Phase 2 mCRC study to track ctDNA dynamics and molecular response patterns tied to treatment.
• Natera will deliver customized real-world data analyses from its oncology database to inform trial design, biomarker selection, and development strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.